Biocon is India's premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.

The Company is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to provide access to affordable treatment to patients worldwide.

Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN^®, insulin analogue Glargine, BASALOG^® and India's first indigenously produced monoclonal antibody BioMAb-EGFR^® , for head & neck cancer. INSUPen^® is a next generation affordable insulin delivery device introduced in India by Biocon.

With a risk balanced business model comprising small molecules, biosimilars, novel molecules, branded formulations and research services, Biocon has evolved into an emerging global biopharma enterprise, serving its partners and customers in over 70 countries.